Bioventus (NYSE:BVS) Stock Price Down 5.9% – Should You Sell?

Bioventus Inc. (NYSE:BVS)’s stock price traded down 5.9% during mid-day trading on Wednesday . The company traded as low as $9.97 and last traded at $10.16. 258,471 shares changed hands during trading, a decline of 38% from the average session volume of 418,376 shares. The stock had previously closed at $10.80.

Analysts Set New Price Targets

Separately, JPMorgan Chase & Co. upgraded Bioventus from an “underweight” rating to a “neutral” rating and raised their price objective for the stock from $12.00 to $13.00 in a research note on Tuesday, December 17th.

Bioventus Price Performance

The company has a quick ratio of 0.99, a current ratio of 1.41 and a debt-to-equity ratio of 1.85. The stock has a market capitalization of $779.90 million, a price-to-earnings ratio of -15.75 and a beta of 0.86. The business’s 50 day simple moving average is $10.10 and its 200-day simple moving average is $11.00.

Insider Buying and Selling

In other news, SVP Anthony D’adamio sold 4,380 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total transaction of $44,632.20. Following the completion of the transaction, the senior vice president now owns 118,178 shares of the company’s stock, valued at approximately $1,204,233.82. The trade was a 3.57 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Robert E. Claypoole sold 28,786 shares of the company’s stock in a transaction on Monday, January 13th. The stock was sold at an average price of $9.10, for a total value of $261,952.60. Following the sale, the chief executive officer now owns 64,964 shares of the company’s stock, valued at approximately $591,172.40. This represents a 30.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 52,932 shares of company stock worth $512,511. Corporate insiders own 32.90% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. HighTower Advisors LLC grew its holdings in shares of Bioventus by 11.3% during the 4th quarter. HighTower Advisors LLC now owns 13,617 shares of the company’s stock valued at $143,000 after purchasing an additional 1,380 shares during the last quarter. Principal Financial Group Inc. boosted its position in Bioventus by 9.4% in the fourth quarter. Principal Financial Group Inc. now owns 19,228 shares of the company’s stock valued at $202,000 after buying an additional 1,652 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Bioventus by 106.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,469 shares of the company’s stock worth $36,000 after buying an additional 1,786 shares during the last quarter. EP Wealth Advisors LLC increased its holdings in shares of Bioventus by 17.0% during the fourth quarter. EP Wealth Advisors LLC now owns 14,096 shares of the company’s stock worth $148,000 after buying an additional 2,047 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of Bioventus by 26.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 15,194 shares of the company’s stock valued at $160,000 after acquiring an additional 3,153 shares during the last quarter. Institutional investors and hedge funds own 62.94% of the company’s stock.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.